IDH1 and astrocytoma (excluding glioblastoma): However, the CNS WHO 5 has classified IDH‐mutant gliomas into oligodendroglioma and astrocytoma, and glioblastomas are all IDH wild type, so glioblastomas cannot benefit from ivosidenib, but for oligodendroglioma and astrocytoma, this is undoubtedly a breakthrough in the treatment.